BM41 is developed by Odense University Hospital.

What development phase is BM41 in?

BM41 is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BM41

Odense University Hospital · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	BM41
Sponsor	Odense University Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BM41 CI brief — competitive landscape report
BM41 updates RSS · CI watch RSS
Odense University Hospital portfolio CI